Reprogram Biosciences develops in-vivo cell reprogramming therapies that convert cancer cells into immune cells directly within the body. This novel approach aims to create safer and more accessible treatments by turning diseased cells into therapeutic agents.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often involve external procedures and can be limited by safety concerns and accessibility issues. Traditional methods may not fully leverage the body's own immune system to combat solid tumors effectively. The cost and complexity of existing cancer therapies can also pose significant challenges for patients and healthcare systems.
Solution
Reprogram Biosciences is developing in-vivo cell reprogramming therapies designed to convert cancer cells into immune cells directly within the patient's body. This innovative approach aims to transform tumors into allies by using a novel therapeutic gene cocktail to reprogram cancer cells into antigen-presenting cells (APCs), T-cells, and NK cells. The company utilizes a cutting-edge lipid nanoparticle (LNP) system for targeted delivery of the therapeutic gene to solid tumors, ensuring precision and efficacy. By empowering the body’s own defenses, Reprogram Biosciences seeks to provide safer, more accessible, and cost-effective cancer treatments, potentially eliminating the need for external procedures and improving patient outcomes. Preclinical models have demonstrated prolonged survival, suggesting a promising future for this immunotherapy approach.
Target Audience
The primary target audience includes patients with solid tumors and the healthcare providers who treat them, particularly those seeking innovative and less invasive cancer therapies.
Features
- CELLReprogrammer Platform: AI/ML-based cell reprogramming technology.
- Novel therapeutic gene cocktail to transform cancer cells into APCs, T-cells, and NK cells.
- Targeted delivery of therapeutic genes to solid tumors using a lipid nanoparticle (LNP) system.
- Off-the-shelf therapeutics for ready-to-use, time-efficient, and cost-effective treatment.